SCHEMBL25560273

SCHEMBL25560273

Cc1cnc(C(=O)O)nc1-c1ccc(N)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMO O15229 5/20 0.40
▸ NEK2 P51955 2/20 0.37
▸ KDM4E B2RXH2 3/20 0.37
▸ ALDH1A1 P00352 3/20 0.37
▸ GAA P10253 3/20 0.37
▸ NPC1 O15118 2/20 0.37
▸ POLB P06746 2/20 0.37
▸ RAB9A P51151 2/20 0.37
▸ GLA P06280 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ CTSL P07711 1/20 0.37
▸ CTSB P07858 1/20 0.37
▸ GABRP O00591 2/20 0.37
▸ GABRD O14764 2/20 0.37
▸ GABRA1 P14867 2/20 0.37
▸ GABRB1 P18505 2/20 0.37
▸ GABRG2 P18507 2/20 0.37
▸ GABRB3 P28472 2/20 0.37
▸ GABRA5 P31644 2/20 0.37
▸ GABRA3 P34903 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25252045 0.87 KDM4E (0.45) KMOKDM4EALDH1A1GAAPOLB
SCHEMBL24572723 0.85 NTRK1 (0.45) KMOKDM4EALDH1A1SMN1; SMN2MAPT
SCHEMBL25250193 0.84 KMO (0.46) KMOALDH1A1GABRA5
SCHEMBL32680058 0.84 KMO (0.46) KMOALDH1A1GABRA5
SCHEMBL25559336 0.81 KMO (0.46) KMONEK2KDM4EALDH1A1GAA
SCHEMBL25552017 0.81 PDK1 (0.45) KMOGAAPDK1
SCHEMBL30036156 0.81 PDK1 (0.45) KMOGAAPDK1
SCHEMBL25560594 0.79 KMO (0.36) KMOKDM4EALDH1A1GAANPC1
SCHEMBL30036709 0.78 KMO (0.63) KMONEK2ALDH1A1
SCHEMBL25559406 0.78 KMO (0.49) KMONEK2JAK2JAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159508-A1 INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2023-05-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159508-A1 INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE RIPK1, RIPK2, RIPK4 KMO 3071/4885NEK2 319/4885KDM4E 3689/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback